Possible therapeutic vaccines for canine myasthenia gravis: implications for the human disease and associated fatigue.

Possible therapeutic vaccines for canine myasthenia gravis: implications for the human disease and associated fatigue. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Possible therapeutic vaccines for canine myasthenia gravis: implications for the human disease and associated fatigue. Abstract Text:

F Shawn Galin,Cheryl L Chrisman,James R Cook,Likang Xu,Patricia L Jackson,Brett D Noerager,Nathaniel M Weathington,J Edwin Blalock,

Myasthenia gravis (MG) is caused by T cell-dependent antibodies reactive with acetylcholine receptors. These autoreactive antibodies cause muscle weakness by interfering with neuromuscular transmission via removal of acetylcholine receptors from the neuromuscular junction as well as changing the architecture of the junction itself. Consequently, muscle fatigue is a debilitating aspect of MG often leading to more general feelings of tiredness not directly due to muscle weakness. We have previously described two peptides that are mimetics of antigen receptors on certain autoreactive T and B cells that are involved in MG. When used as vaccines in the rat model of MG, these peptides prevented and ameliorated disease and muscle fatigue by blunting acetylcholine receptor antibody responses. Such disease protection resulted from vaccine-induced anergizing antibodies against acetylcholine receptor-specific T and B cell antigen receptors. The present study prospectively evaluated the efficacy of these two vaccines in spontaneous acquired MG in pet dogs. When compared to historical controls that were prospectively studied, the vaccines increased the proportion of remitted dogs from 17 to 75%. In comparison to retrospectively studied historical controls that spontaneously remitted from MG, the vaccines accelerated the rate of decline in acetylcholine receptor antibody titers which resulted in a 3-fold decrease in the mean time to remission. These results are suggestive of a new type of targeted therapy that can drive autoimmune responses into long-term remission and possibly afford a means of determining whether correction of a physical cause of muscle weakness also corrects the perception of chronic, generalized fatigue.

Possible therapeutic vaccines for canine myasthenia gravis: implications for the human disease and associated fatigue. Publishing Authors By Initials

FS Galin,CL Chrisman,JR Cook,L Xu,PL Jackson,BD Noerager,NM Weathington,JE Blalock,

For similar complex mixtures: biological products: vaccines research abstracts see: complex mixtures: biological products: vaccines research

PUBMED ID PMID:

MEDLINE DATE:

Possible therapeutic vaccines for canine myasthenia gravis: implications for the human disease and associated fatigue. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Brain, behavior, and immunity

VOLUME: 21

Page Numbers: 323-31

Journal Abbreviation: Brain Behav. Immun.

ISSN: 0889-1591

DAY: 20

MONTH: 11

YEAR: 2006

Possible therapeutic vaccines for canine myasthenia gravis: implications for the human disease and associated fatigue. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 8800478

Possible therapeutic vaccines for canine myasthenia gravis: implications for the human disease and associated fatigue. Keywords Mesh Terms:

KEYWORDS: Vaccines

MESH TERMS: therapeutic use

Chemical & Substance for Abstract: Possible therapeutic vaccines for canine myasthenia gravis: implications for the human disease and associated fatigue. Information

Substance Name: Vaccines

Registry Number: 0

Grant and Affiliation Information for Possible therapeutic vaccines for canine myasthenia gravis: implications for the human disease and associated fatigue.

AFFILIATION: Department of Physiology and Biophysics, University of Alabama at Birmingham, 1918 University Blvd., MCLM 896, Birmingham, AL 35294-0005, USA.

Country: United States

AGENCY: United States NHLBI

GRANT: T32HL007553

ACRONYM: HL

MEDLINETA: Brain Behav Immun

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Possible therapeutic vaccines for canine myasthenia gravis: implications for the human disease and associated fatigue Related Publications

• A novel proteolytic cascade generates an extracellular matrix-derived chemoattractant in chronic neutrophilic inflammation.
• Adenocarcinoma of the middle third of the esophagus arising from ectopic gastric mucosa.
• Aspiration of blood from pericardium in treatment of acute cardiac tamponade after injury; further experience, with report of cases.
• Cancer of the stomach.
• Complete transposition of the aorta and the pulmonary artery; experimental observations on venous shunts as corrective procedures.
• Hematology as an aid in the diagnosis of poultry diseases.
• Interfering with extracellular matrix degradation to blunt inflammation.
• Methodology of an ongoing, randomized controlled trial to prevent falls through enhanced pharmaceutical care.
• Neuhauser Lecture: Tetralogy of Fallot: early history and late results.
• Possible therapeutic vaccines for canine myasthenia gravis: implications for the human disease and associated fatigue.
• Post hoc pattern matching: assigning significance to statistically defined expression patterns in single channel microarray data.
• Potential role of high-mobility group box 1 in cystic fibrosis airway disease.
• Predictors of calcium intake patterns: a longitudinal analysis.
• Risky eating behaviors of young adults-implications for food safety education.
• Surgical procedures employed and anatomical variations encountered in the treatment of congenital pulmonic stenosis.
• Surgical treatment of pulmonic stenosis.
• The chemotherapy of leukemia.
• The structured interview and interviewer training in the admissions process.
• The surgical treatment of congenital pulmonic stenosis.
• [Not Available.]
• [Not Available.]
• [Recent advances in cardiovascular surgery.]